Novartis: Arthritis, Rheumatoid trials
The registry lists 30 Arthritis, Rheumatoid studies with Novartis as lead sponsor. 1 are open to participants now and 17 have results posted.
Phase 1 14Phase 2 16Phase 3 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)Not yet recruitingNCT07923747Phase 1
- Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid ArthritisCompletedNCT02744755Phase 3Results posted
- Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid ArthritisCompletedNCT02638259Phase 3Results posted
- GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®CompletedNCT02514772Phase 3Results posted
- 99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)TerminatedNCT02328027Phase 1/2Results posted
- Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.TerminatedNCT01770379Phase 3Results posted
- A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) PatientsCompletedNCT01426789Phase 2Results posted
- Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα AgentsCompletedNCT01377012Phase 3Results posted
- Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking MethotrexateCompletedNCT01359943Phase 2Results posted
- Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)CompletedNCT01350804Phase 3Results posted
- GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard TherapyCompletedNCT01274182Phase 1/2Results posted
- Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid ArthritisCompletedNCT01023256Phase 1/2Results posted
- Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)CompletedNCT00928512Phase 2Results posted
- Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis PatientsCompletedNCT00669942Phase 1/2Results posted
- Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid ArthritisCompletedNCT00554606Phase 2Results posted
- Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid ArthritisCompletedNCT00504595Phase 2Results posted
- Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid ArthritisCompletedNCT00487825Phase 2Results posted
- Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid ArthritisCompletedNCT00424346Phase 2Results posted
- A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's DiseaseActive, not recruitingNCT07048197Phase 1/2
- An Ascending Dose Study of PIT565 in Participants With Rheumatoid ArthritisActive, not recruitingNCT07029555Phase 1
- Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune DiseaseActive, not recruitingNCT06293365Phase 2
- Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid ArthritisCompletedNCT03574545Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis PatientsCompletedNCT02675803Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis PatientsCompletedNCT02089087Phase 1
- Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)CompletedNCT00959439Phase 1
- To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting ConditionsCompletedNCT00946686Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With MethotrexateCompletedNCT00619905Phase 1/2
- Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid ArthritisTerminatedNCT00505089Phase 1/2
- 6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid ArthritisCompletedNCT00170872Phase 3
- A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.CompletedNCT00154336Phase 2